| Outcome Measures: |
Primary: Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans, Activation of BAT, as considered Standard Uptake Value (SUV) threshold of 2.0 on 18-FDG-PET CT, prior to liraglutide use and after 2 weeks on liraglutide 3.0 mg, 2 weeks | Secondary: Evaluate the effect of liraglutide administration on hypothalamic activation in humans, Evaluate the effect of liraglutide administration on hypothalamic tract activation as assessed by magnetic resonance image in humans prior and after 2 weeks on liraglutide 3.0 mg, 2 weeks|Evaluate the effect of liraglutide administration on non-shivering thermogenesis in humans, Evaluate the effect of liraglutide administration on non-shivering thermogenesis by infrared thermography and indirect calorimetry in humans prior and after 2 weeks on liraglutide 3.0 mg, 2 weeks|Evaluate the effect of liraglutide administration on body weight in humans, Evaluate the effect of liraglutide administration on total body weight (kg) in humans prior and after 2 weeks on liraglutide 3.0 mg, 2 weeks|Evaluate the effect of liraglutide administration on metabolic basal rate in humans, Evaluate the effect of liraglutide administration on basal kilocalories/day in humans prior and after 2 weeks on liraglutide 3.0 mg, 2 weeks|Evaluate the effect of liraglutide administration on body composition in humans, Evaluate the effect of liraglutide administration on lean mass and fat percentage as assessed by dual x-ray absorptiometry (DXA) in humans prior and after 2 weeks on liraglutide 3.0 mg, 2 weeks
|
